The interest follows a high-profile summer for the Halifax-based company, which showcased its expanded diagnostic capabilities at the ISTH 2026 conference in Paris. CEO Paul Empey noted that coagulation labs are increasingly prioritizing chromogenic assays to maintain accuracy amidst the introduction of FVIIIa mimetics. The company’s recent scientific presentations, including research on automated lupus anticoagulant assays and modified Nijmegen-Bethesda tests, highlight a broader strategy to support evolving laboratory requirements.

Beyond diagnostic technology, the organization is leveraging its subsidiaries to tighten its grip on the market. Following the 2025 acquisition of George King Bio-Medical, the company has integrated specialized manufacturing from Affinity Biologicals with a direct line to the bleeding disorders patient community. This network was on display at the ADLM 2026 conference in Anaheim and the NBDF Bleeding Disorders Conference in Orlando, where the focus shifted toward the critical role of plasma donation in driving future diagnostic breakthroughs.